PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as augmented reality industrial solutions. Founded in 1985, PTC has 28,000 customers, ...

Earlier this month, PTC announced that HOLON, a BENTELER Group subsidiary, adopted its Windchill+ cloud PLM to develop a Level-4 autonomous EV, while PTC also introduced an AI Engine for its Arena PLM ...

Most Americans agree: This economy stinks. Practically every consumer sentiment survey and political poll points to that theme. People feel like their dollars aren’t stretching as far as before, and ...

It has been about a month since the last earnings report for PTC Inc. (PTC). Shares have added about 2.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...

Private equity firm TPG is to buy Kepware and ThingWorx from PTC for up to $725 million. It marks a final shift in PTC’s Industry 4.0 strategy, and a tightening of focus on its industrial PLM ...

PTC is selling off its IoT businesses, Kepware and ThingWorx, in order to hone its focus on SaaS and AI, according to CEO Neil Barua, as the conglomerate announced a sale of the operations to asset ...

TPG has agreed to acquire PTC’s industrial connectivity and IoT businesses. No financial terms were disclosed. Headquartered in Boston, PTC is a software company. Neil Barua serves as president and ...

Wes Allen, Alabama’s Secretary of State, is releasing a tutorial video titled, “Business Basics: Structures and Business Filings,” aimed at providing support and guidance to Alabama’s small business ...

Git isn’t hard to learn. Moreover, with a Git GUI such as Atlassian’s Sourcetree, and a SaaS code repository such as Bitbucket, mastery of the industry’s most powerful version control tools is within ...

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. Despite its efforts, the FDA has snubbed the ...

The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid anyway. The FDA has rejected PTC Therapeutics’ vatiquinone, the company’s ...